Full-Time
Business System Owner HighRadius Cloud Manager
Updated on 7/12/2026
Sanofi
10,001+ employees
Global pharma company; vaccines and R&D
No salary listed
Hyderabad, Telangana, India
In Person
On-site in Hyderabad, India. No remote work.
 Accounting (1) |
|---|
People at Sanofi
People at Sanofi who can refer or advise you
- Strong understanding of Collections and Cash Application processes within the Order to Cash cycle
- Deep knowledge of HighRadius Cloud (Collections and Cash Application modules)
- SLA governance experience and project management across large-scale global deployments
- Solution and user expertise sustainability by monitoring global adoption (target: 85%+ daily collector login) and platform performance
- Ability to collaborate with multiple stakeholders including GPLs, GPO, Digital team, and HighRadius vendor
- Excellent English written and verbal communication skills
- Leverage HighRadius Cloud solution capabilities, including automation and AI-driven analytics, to bring value to Collections and Cash Application activities on a daily basis
- Oversee business activities in the context of the HighRadius upgrade across 80+ countries to drive collector adoption, reduce DSO, and improve cash application automation, in collaboration with K-users, Digital, and the HighRadius vendor
- Represent the single point of contact of the GPO organization toward our Digital team and HighRadius
- Consult with the GPLs to assess and anticipate current and future capability requirements and develop a long-term plan with aligned priorities across 80+ countries
- Identify opportunities to implement advanced automation capabilities including AI-driven customer segmentation, predictive payment analytics, and automated dunning sequences
- Maintain HighRadius as the single source of truth for all collection strategies, worklist configurations, and cash application rules
- Define KPI frameworks, validate data accuracy, and deliver actionable dashboards aligned to operational and management requirements
- Promote Core Model processes and ensure standardized collection ways of working globally
- Coordinate implementation of HighRadius automation features including smart worklist configuration, automated dunning sequences, cash application matching rules, and deduction management workflows
- Organize Analysts activities to gather business requirements from SMEs, GPLs, Product Owner to secure maturity and buy-in before configuration
- Lead UAT phases by preparing Key User trainings, test scripts, coordinating testers, following up and reporting execution and incident resolution
- Ensure successful ramp-up by establishing strategy with stakeholders and supporting teams post go-live
- Gather feedback from stakeholders regarding potential improvements of the HighRadius solution and monitoring post-launch initiatives
- Monitor post-launch metrics such as overdue improvement, collector productivity, and cash application auto-match rates
- Manage KPI data foundation build and data coming from HighRadius; ensure reporting and analytics needs are met across regions
- Identify business cases for functionalities to be implemented with GPLs and align with product owner priorities
- Ensure training documentation is accurate and updated; provide additional training as needed
- Communicate feature delivery to stakeholders and serve as single point of contact for HighRadius platform-related concerns
- Mentor and manage talent development within the BSO Analysts team
- Foster collaboration, trust, and teamwork across the team; focus on employee retention and engagement
- Languages: Excellent English written and verbal
- Support Digital HighRadius vendor relationship and SLA compliance; enforce SLA across incident priorities; participate in monthly service reviews and quarterly business reviews; document configuration changes and change requests; manage Change Request pipeline with 80%+ of approved CRs delivered on time; coordinate HighRadius tickets in ServiceNow with proper priority classification, RCA documentation, and timely resolution
- Enforce regression testing and internal QA before UAT for all platform changes
- Ensure dedicated senior HighRadius consultants are assigned with knowledge transfer protocols
- Supervise and coach BSO Analysts; participate in recruitment, evaluate performance, and develop talent
- Promote culture of collaboration and effective communication; focus on retention and engagement
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
People at Sanofi
People at Sanofi who can refer or advise you
Simplify's Take
What believers are saying
- EU approval for Cenrifki as first disability-targeting MS drug without relapses drives significant revenue in neurology segment.
- Wayrilz approval in Japan for immune thrombocytopenia with 23% durable response expands rare disease portfolio globally.
- Dupixent expansion into Type 2 indications including COPD and eosinophilic diseases drives immunology revenue to $4.67B.
What critics are saying
- EU antitrust investigation into flu vaccine promotion threatens €50M+ fines and forced marketing restrictions within 24-36 months.
- US regulatory rejection for Cenrifki blocks $1.2B SPMS revenue, forcing reliance on EU-only launch with liver safety burdens.
- Dupixent patent cliff post-2028 risks $17B peak sales erosion unless late-stage immunology assets execute flawlessly by 2028.
What makes Sanofi unique
- Sanofi leads globally in vaccine innovation with one-third of pipeline focused on immunization and transformative vaccines.
- Sanofi uniquely combines AI-native R&D expertise via new chief Paulo Fontoura from Xaira Therapeutics to accelerate pipeline.
- Sanofi differentiates with three 'pipeline-in-a-product' assets exceeding €5B peak sales potential in immunology and neurology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]
Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.
The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.
The European Commission has granted conditional marketing authorisation for Sanofi's Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 years and older weighing at least 40 kg. The treatment is approved for patients when other options provide limited benefit or have been exhausted. The approval follows a positive opinion from the European Medicines Agency and is based on the ROCKstar phase 2 study, which demonstrated a 74% overall response rate. Nearly half of chronic GVHD patients require third-line treatment, yet therapeutic options have remained limited in the EU. Rezurock is already approved in 20 countries, including the US, UK and Canada. More than 20,000 patients have been treated with the medicine since its first US approval in July 2021.
Bernstein analyst Justin Smith has initiated coverage of Sanofi with an "Outperform" rating and a price target of €110, representing 37% upside from current levels. The analyst believes the French biopharmaceutical company's new chief executive will unlock shareholder value. Sanofi appointed Belén Garijo, former CEO of Germany's Merck KGaA, as its new chief executive in February. The 65-year-old Spanish executive will take charge in late April, replacing Paul Hudson after his six-year tenure. The company says Garijo will strengthen productivity, governance and innovation capacity in research and development. Sanofi shares have declined over 4.5% since the beginning of 2025. The stock trades at a forward price-to-earnings ratio of 9.26.